Risk of Developing GDM Gestational Diabetes Mellitus in Singleton and Twin Gestation with Use of 17 Hydroxyprogesterone Caproate

Hafiza Asifa Saleem; Viqar Ashraf; Rabia Sajjad; Sadia Zainab Ch; Naheed Hayat; Hafiz Muhammad Asif Rehman

doi:10.70749/ijbr.v3i5.1305

Authors

Hafiza Asifa Saleem Department of Obstetrics and Gynecology, CMH Bahawalpur, Pakistan.
Viqar Ashraf Department of Obstetrics and Gynecology, PEMH Rawalpindi, Pakistan.
Rabia Sajjad Department of Obstetrics and Gynecology, CMH Lahore, Pakistan.
Sadia Zainab Ch Department of Obstetrics and Gynecology, CMH Bahawalpur, Pakistan.
Naheed Hayat Department of Obstetrics and Gynecology, CMH Bahawalpur, Pakistan.
Hafiz Muhammad Asif Rehman Department of Pharmacy, Government College University, Faisalabad, Pakistan.

DOI:

https://doi.org/10.70749/ijbr.v3i5.1305

Keywords:

GDM, 17 P, Preterm Birth Prevention, Placebo-Controlled Trial, Singleton and Multiple Gestations

Abstract

Background: The use of 17P to prevent preterm birth is well-documented, but its potential effect on the development of GDM is not well understood. Objective: This study was planned with object to deeply study the effect of 17P on the occurrence of GDM in pregnant women, comparing its effects to a placebo in both single and multiple pregnancies. Methodology: In this prospective short study, total 198 pregnant females were recruited. Study group 17P and placebo group formed thorough randomization and the gestation age was between 16 to 36 weeks. The primary outcome measured was the occurrence of GDM, diagnosed via the OGTT administered during the 24th to 28th weeks of pregnancy. Results: GDM was observed in 16.33% of the participants in the 17P group, while it was observed in 18% of those in the placebo group, with no statistically significant difference observed (p=0.755). Subgroup analyses considering factors such as type of pregnancy, obesity, and history of diabetes also showed similar non-significant outcomes. Conclusion: The findings indicate that 17-alpha Hydroxy Progesterone Caproate does not significantly affect the development of GDM in pregnant females. These results support the continued use of 17P in pregnancies at risk of premature birth without increasing the risk of GDM.

Downloads

Download data is not yet available.

References

American Diabetes Association. Classification and diagnosis of diabetes: Standards of medical care in diabetes-2020. Diabetes Care. 2020;43 (Supplement 1) :S14-S31.

https://doi.org/10.2337/dc20-s002

Feig DS, Zinman B, Wang X, Hux JE. Risk of development of diabetes mellitus after diagnosis of gestational diabetes. CMAJ. 2014;179(3):229-234.

https://doi.org/10.1503/cmaj.080012

Meis PJ, Klebanoff M, Thom E, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med. 2003;348(24):2379-2385.

https://doi.org/10.1056/nejmoa035140

Rebarber A, Istwan NB, Russo-Stieglitz K, et al. Increased incidence of gestational diabetes in women receiving prophylactic 17-alpha hydroxyprogesterone caproate for prevention of recurrent preterm delivery. Diabetes Care. 2007;30(9):2277-2280. https://doi.org/10.2337/dc07-0564.

American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No.190: Gestational diabetes mellitus. Obstet Gynecol. 2018;131(2):e49-e64.

https://doi.org/10.1097/aog.0000000000002501

Donovan L, Hartling L, Muise M, et al. Screening tests for gestational diabetes: A systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2013;159(2):115-122.

https://doi.org/10.7326/0003-4819-159-2-201307160-00657

Ehrenberg HM, Durnwald CP, Catalano P, Mercer BM. The influence of obesity and diabetes on the risk of cesarean delivery. Am J Obstet Gynecol. 2013;207(3):211.e1- 211.e7.

https://doi.org/10.1016/j.ajog.2004.06.057

Landon MB, Spong CY, Thom E, et al. A multicenter, randomized trial of treatment for mild gestational diabetes. N Engl J Med. 2009;361(14):1339-1348.

https://doi.org/10.1056/nejmoa0902430

HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med. 2008;358(19):1991-2002.

https://doi.org/10.1097/ogx.0b013e318187b7a2

Crowther CA, Hiller JE, Moss JR, et al. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med. 2005;352(24):2477-2486.

https://doi.org/10.1056/nejmoa042973

Carpenter MW, Coustan DR. Criteria for screening tests for gestational diabetes. Am J Obstet Gynecol. 1982;144(7):768-773.

https://doi.org/10.1016/0002-9378(82)90349-0

Metzger BE, Buchanan TA. Summary and recommendations of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus. Diabetes Care. 1996;19(4):500-510.

https://doi.org/10.2337/diab.40.2.s197

Rebarber, A., Istwan, N. B., Russo-Stieglitz, K., Cleary-Goldman, J., Morgan, M. A., & Devine, P. C. (2007). Increased incidence of gestational diabetes in women receiving prophylactic 17-alpha hydroxyprogesterone caproate for prevention of recurrent preterm delivery. Diabetes Care, 30:(9), 2277-2280.

https://doi.org/10.2337/dc07- 0564

Sibai B, Saade GR, Das AF, Gudeman J. Safety review of hydroxyprogesterone caproate in women with a history of spontaneous preterm birth. J Perinatol. 2020;40(10):1441-1447.

https://doi.org/10.1038/s41372-020-00849-y

Feghali M, Venkataramanan R, Caritis S. Prevention of preterm delivery with 17- hydroxyprogesterone caproate: pharmacologic considerations. Semin Perinatol. 2014;38(8):511-521.

https://doi.org/10.1053/j.semperi.2014.08.013

Brawerman GM, Dolinsky VW. Therapies for gestational diabetes and their implications for maternal and offspring health: Evidence from human and animal studies. Semin Cell Dev Biol. 2018;84:1-11.

https://doi.org/10.1016/j.phrs.2018.02.002

Hall NR. What agent should be used to prevent recurrent preterm birth: 17-P or natural progesterone? Clin Perinatol. 2011;38(3):561-570.

https://doi.org/10.1016/j.ogc.2011.02.014

Caritis SN, Feghali MN, Grobman WA, Rouse DJ. What we have learned about the role of 17-alpha-hydroxyprogesterone caproate in the prevention of preterm birth. Semin Perinatol. 2016;40(5):313-319.

https://doi.org/10.1053/j.semperi.2016.03.002

Badmus OO, Anoka NA, Olufunmilayo OM, Lawrence OA. Insulin resistance and depressed cardiac G6PD activity induced by glucocorticoid exposure during pregnancy. J Steroid Biochem Mol Biol. 2020;200:105724.

https://doi.org/10.1016/j.etap.2020.103423

Olufunto BO, Michael OS, Rabiu S, Olatunji LA. Gestational glucocorticoid exposure disrupts glucose homeostasis. J Steroid Biochem Mol Biol. 2020;190:33- 41.

https://doi.org/10.1016/j.etap.2018.04.013

Gyamfi C, Horton AL, Momirova V, Rouse DJ, Caritis SN, Peaceman AM, et al. The effect of 17-alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. Am J Obstet Gynecol. 2009;201(4):392.e1- 392.e6.

https://doi.org/10.1016/j.ajog.2009.06.036

Pergialiotis V, Bellos I, Hatziagelaki E, Antsaklis A, Loutradis D, Daskalakis G. Progestogens for the prevention of preterm birth and risk of developing gestational diabetes mellitus: a meta-analysis. Am J Obstet Gynecol. 2019;221(5):429-36.

https://doi.org/10.1016/j.ajog.2019.05.033

Eke AC, Sheffield J, Graham EM. 17α-Hydroxyprogesterone caproate and the risk of glucose intolerance in pregnancy: a systematic review and meta-analysis. Obstet Gynecol. 2019;133(3):468-75.

https://doi.org/10.1097/aog.0000000000003115

Waters TP, Schultz BA, Mercer BM, Catalano PM. Effect of 17α- hydroxyprogesterone caproate on glucose intolerance in pregnancy. Obstet Gynecol. 2009;114(1):45-9.

https://doi.org/10.1097/aog.0b013e3181a9454b

Rouholamin S, Zarean E, Sadeghi L. Evaluation the effect of 17-alpha hydroxyprogesterone caproate on gestational diabetes mellitus in pregnant women at risk for preterm birth. Adv Biomed Res. 2015;4(1):242.

https://doi.org/10.4103/2277-9175.168609